Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
362 Leser
Artikel bewerten:
(1)

Medicover: Interim Report January-March 2020

STOCKHOLM, April 30, 2020 /PRNewswire/ --

  • Revenue increased by 19.6% to €238.8m (€199.7m). Organic revenue grew by 5.8%.
  • Operating profit (EBIT) was €6.4m (€11.3m), representing an operating margin of 2.7% (5.6%).
  • Net result amounted to €-2.5m (€6.9m), which represents a net result margin of -1.0% (3.4%).
  • EBITDA increased by 5.6% to €29.0m (€27.5m), corresponding to an EBITDA margin of 12.2% (13.8%).
  • EBITDAaL was €16.8m (€18.5m), corresponding to an EBITDAaL margin of 7.0% (9.2%).
  • Net cash flow from operating activities was €36.5m (€24.1m).
  • Basic/diluted loss per share were €-0.006 (earnings €0.046).
  • Covid-19 pandemic has a significant impact on operating performance.

REVENUE AND EARNINGS

€ millions (€m)

Q1 2020

Q1 2019

Variance

FY 2019

Revenue

238.8

199.7

20%

844.4

Operating profit (EBIT)

6.4

11.3

-43%

46.5

Operating profit margin

2.7%

5.6%


5.5%

Net result

-2.5

6.9

-136%

24.7

Net result margin

-1.0%

3.4%


2.9%

Basic/diluted earnings/(loss) per share, €

-0.006

0.046

-113%

0.168






EBITDA

29.0

27.5

6%

120.7

EBITDA margin

12.2%

13.8%


14.3%

EBITDAaL

16.8

18.5

-9%

80.6

EBITDAaL margin

7.0%

9.2%


9.5%

EBITA

8.9

12.5

-29%

53.7

EBITA margin

3.7%

6.3%


6.4%

Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information. As from Q3 2019 margins (including margins of comparative figures) and growth rates have been calculated based on EUR whole figures instead of figures rounded in millions.

This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CEST) on 30 April 2020. This interim report and other information about Medicover is available at medicover.com.

Contact information

For further information, please contact:

Hanna Bjellquist
Head of Investor Relations
Phone: +46-70-303-32-72
E-mail: hanna.bjellquist@medicover.com

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories and the largest markets are Poland and Germany. In 2019, Medicover had revenue around €844 million and 28,800 employees. For more information, go to www.medicover.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medicover/r/interim-report-january-march-2020,c3101087

The following files are available for download:

https://mb.cision.com/Main/15662/3101087/1239343.pdf

Interim report January-March 2020

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.